Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saurabh Kumar has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glutathione redox system as a therapeutic target for Plasmodium: Opportunities, Challenges, and future perspectives

    by Richa Prasad Mahato, Soniya Kumbham, Saurabh Kumar, Sanjay Ch

    Glutathione (GSH) serves as an essential guardian for parasites, protecting them from the onslaught of oxidative stress. As hemoglobin breaks down and energy is harvested through the intricate mitochondrial respiratory pathway, GSH meticulously creates a reducing environment, akin to a fortress against oxidative damage. The metabolic pathways involving GSH in parasites are complex and markedly different from those in human hosts, rendering them a compelling target in the battle against multidrug-resistant parasites. This review illuminates the critical role of GSH in the survival of malaria parasites and the impact of key enzyme inhibitors on the GSH redox pathway. Recent discoveries surrounding significant enzyme inhibitors as GST, GR, GS, and GP, are explored, shedding light on the potential of combination therapies while underscoring the obstacles posed by selective drug targeting and the imperative to navigate drug resistance. Moreover, the review delves into the forefront of research on the metabolic pathways of GSH in parasites, unveiling a trove of promising drug targets for strategies aimed at treating malaria in an era plagued by multidrug resistance and offers hope for innovative therapeutic approaches against one of the world’s most persistent diseases.


  • The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice

    by Weiqing Jing, Jocelyn A. Schroeder, Saurabh Kumar, Juan Chen, Yuanhua Cai, Lynn M. Malec, Alexander L. Dent, Weiguo Cui, Qizhen Shi

    Abstarct: Developing anti–factor VIII (FVIII) inhibitory antibodies (inhibitors) are a significant complication of FVIII protein replacement therapy in hemophilia A. Our previous study demonstrated that follicular helper T (TFH) cells play a critical role in FVIII inhibitor development. Follicular regulatory T (TFR) cells are a subset of forkhead box protein P3 positive (Foxp3+) T cells identified in the germinal center that can modulate TFH cell activation of B cells and antibody development. Here, we report that FVIII immunization significantly increases the TFR cells in the spleens of FVIII inhibitor-producing FVIIInull mice compared with saline-treated controls and non–inhibitor-producing animals. The TFH/TFR ratio significantly increased in FVIII inhibitor-producing mice. The emergence of TFR cells correlated with titers of FVIII inhibitors in FVIII-immunized mice. Using TFR-deficient Foxp3Cre+Bcl6fl/fl (Bcl6FC) mice, we found that the loss of TFR cells led to significantly decreased FVIII inhibitors compared with wild-type (WT) mice on FVIII immunization (24 ± 16 and 131 ± 114 Bethesda unit (BU)/mL, respectively) but not total anti-FVIII IgG levels and that TFR cells regulated IgG subclass switching and FVIII-specific B-cell responses. Interestingly, on FVIII immunization, mice with phosphatase and tensin (Pten) deficiency in Foxp3+ cells (Foxp3Cre+Ptenfl/fl), a model with augmented TFR cells, developed markedly lower FVIII inhibitor titers (8.1 ± 8.6 BU/mL) than WT controls. When CD4Cre+Bcl6fl/fl mice, a TFH- and TFR-deficient model, were immunized with FVIII, none of the animals developed FVIII inhibitors. In conclusion, FVIII immunization induces TFR cell activation and expansion. TFR cells have a dual function in regulating the development of FVIII inhibitors, and the TFH/TFR pathway is pivotal in FVIII inhibitor development in mice.


  • Top Cited Papers
    Open Access

    Current strategies against multidrug-resistant Staphylococcus aureus and advances toward future therapy

    by Saurabh Kumar, Richa Prasad Mahato, Sanjay Ch, Soniya Kumbham


  • Open Access

    DRUG RESISTANCE AND RESISTANCE REVERSAL STRATEGIES IN MALARIA PARASITE

    by Saurabh Kumar, Richa Prasad Mahato

    The public health care system is currently facing a major problem with malaria. Globally, malarial deaths have decreased by an estimated 40% in the past two decades because of the clinically effective drugs (artemisinin-based combination therapies) against Plasmodium falciparum. In recent years, P falciparum develop resistance against all antimalarial drugs and then becomes developed multidrug resistance that a major challenge. Even though drug discovery programs have made substantial progress in the past decade, the potential for new drugs/combinations to improve the effectiveness of current malaria control strategies. Beyond, we have compiled a comprehensive review of clinically approved anti-malarial drugs with resistance mechanisms and a novel drug-resistance reversal approach in one place to meet this demand. The review aimed to provide detailed information on drug resistance, its regulatory molecular mechanisms responsible for resistance, and the novel available treatment of malaria. In this review, the article will help in developing effective interventions, potential approaches, and strategies to handle antimalarial resistance. This will prevent life-threatening infections.


  • Design and synthesis of novel glycyrrhetinic acid-triazole derivatives that exert anti-plasmodial activity inducing mitochondrial-dependent apoptosis in Plasmodium falciparum

    by Deepak Singh Kapkoti, Saurabh Kumar, Ashish Kumar, Mahendra P. Darokar, Anirban Pal, Rajendra Singh Bhakuni

    Malaria is an enormous threat to public health due to the emergence of Plasmodium falciparum resistance to widely used anti-malarials, such as chloroquine.


  • Open Access

    Role of AMPK in Myocardial Ischemia‐Reperfusion Injury‐Induced Cell Death in the Presence and Absence of Diabetes

    by Nirupama Kandula, Saurabh Kumar, Venkata Kiran Kumar Mandlem, Aneela Siddabathuni, Sanjay Singh, Ramoji Kosuru

    Recent studies indicate cell death is the hallmark of cardiac pathology in myocardial infarction and diabetes. The AMP‐activated protein kinase (AMPK) signalling pathway is considered a putative salvaging phenomenon, plays a decisive role in almost all cellular, metabolic, and survival functions, and therefore entails precise regulation of its activity. AMPK regulates various programmed cell death depending on the stimuli and context, including autophagy, apoptosis, necroptosis, and ferroptosis. There is substantial evidence suggesting that AMPK is down‐regulated in cardiac tissues of animals and humans with type 2 diabetes or metabolic syndrome compared to non‐diabetic control and that stimulation of AMPK (physiological or pharmacological) can ameliorate diabetes‐associated cardiovascular complications, such as myocardial ischemia‐reperfusion injury. Furthermore, AMPK is an exciting therapeutic target for developing novel drug candidates to treat cell death in diabetes‐associated myocardial ischemia‐reperfusion injury. Therefore, in this review, we summarized how AMPK regulates autophagic, apoptotic, necroptotic, and ferroptosis pathways in the context of myocardial ischemia‐reperfusion injury in the presence and absence of diabetes.


  • Open Access

    4-Chlorothymol Exerts Antiplasmodial Activity Impeding Redox Defense System in Plasmodium falciparum

    by Saurabh Kumar, Pooja Rani Mina, Ravi Kumar, Anirban Pal, Ateeque Ahmad, Sudeep Tandon, Mahendra P. Darokar

    Malaria remains one of the major health concerns due to the resistance of Plasmodium species toward the existing drugs warranting an urgent need for new antimalarials. Thymol derivatives were known to exhibit enhanced antimicrobial activities; however, no reports were found against Plasmodium spp. In the present study, the antiplasmodial activity of thymol derivatives was evaluated against chloroquine-sensitive (NF-54) and -resistant (K1) strains of Plasmodium falciparum. Among the thymol derivatives tested, 4-chlorothymol showed potential activity against sensitive and resistant strains of P. falciparum. 4-Chlorothymol was found to increase the reactive oxygen species and reactive nitrogen species level. Furthermore, 4-chlorothymol could perturb the redox balance by modulating the enzyme activity of GST and GR. 4-Chlorothymol also showed synergy with chloroquine against chloroquine-resistant P. falciparum. 4-Chlorothymol was found to significantly suppress the parasitemia and increase the mean survival time in in vivo assays. Interestingly, in in vivo assay, 4-chlorothymol in combination with chloroquine showed higher chemosuppression as well as enhanced mean survival time at a much lower concentration as compared to individual doses of chloroquine and 4-chlorothymol. These observations clearly indicate the potential use of 4-chlorothymol as an antimalarial agent, which may also be effective in combination with the existing antiplasmodial drugs against chloroquine-resistant P. falciparum infection. In vitro cytotoxicity/hemolytic assay evidently suggests that 4-chlorothymol is safe for further exploration of its therapeutic properties.